The 70-‐gene signature is able to predict the risk of locoregional recurrence. We observed a significantly lower incidence of locoregional recurrence in patients with a low risk 70-‐gene signature result compared to those with high risk 70-‐gene signature result, independent of known risk factors. Patients with high risk 70-‐gene signature cancers are eligible for extensive adjuvant treatment (radiotherapy, chemotherapy and/or endocrine therapy) to reduce the risk of distant as well as locoregional recurrence. Patients with low risk 70-‐gene signature cancers are eligible for more limited local treatment strategies.
Publication Name: Cancer Research